- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01839045
Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification
Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept
Descripción general del estudio
Estado
Condiciones
Descripción detallada
As part of the study, 35 mL or 2 1/2 tablespoons of blood will be drawn from your arm at each study visit.
This study has 2 visits. Visit 1 will take about 1 hour. Visit 2 is a follow up visit at 6 months taking about 1 hour.
Visit 1- Screening and Blood Collection:
The following procedures will be done at the clinical research facility:
- The study doctor and/or study staff will explain the study and all the study procedures.
- You will be asked to review, sign and date this informed consent before any procedures are done.
- The study doctor and/or study staff will ask you questions about your health status and medical history and record this information.
- 35 mL or 2 ½ tablespoons of blood will be collected from your arm.
- The samples will not be labeled with your name but a unique identification code, which means they will be given a number which can be linked to you.
Visit 2 - Follow up:
If you have been diagnosed with cancer between visit 1 and visit 2, you will not be required to complete visit 2. If you have been diagnosed with LCIS or DCIS, you will be requested to return for visit 2. Otherwise you will return to the center for visit 2.
The following procedures will be performed:
- You will have a follow-up breast evaluation performed. Your follow-up breast evaluation may occur prior to Visit 2 if you have it performed at a different facility or it may be performed during this study visit.
- The study doctor and/or study staff will assess your health and medical history.
- 35 mL or 2 1/2 tablespoons of blood will be collected from your arm.
- The samples will not be labeled with your name but a unique identification code, which means they will be given a number which can be linked to you.
Your blood sample will be sent to the study Sponsor, Provista Diagnostics, Inc. for testing.
The test results will not be reported back to the study doctor and will not be used to determine or change your treatment. This testing will be done in addition to any routine testing that your study doctor performs. You will not receive the results of these tests.
Up to 350 subjects will take part in this study. Patients will be enrolled at one of seven sites.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85006
- Banner Health
-
-
California
-
Sacramento, California, Estados Unidos, 95816
- Sutter Institute
-
San Diego, California, Estados Unidos, 92103
- Scripps
-
Santa Barbara, California, Estados Unidos, 93102-1200
- Sansum Clinic
-
-
Massachusetts
-
Peabody, Massachusetts, Estados Unidos, 01960
- Lahey Clinic
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Rhode Island Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Avera Research Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Adult women from 25 years of age to below 50 years of age
- Breast evaluation results of ACR BI-RADS® Category 3 or 4 by imaging and physicians clinical and radiological evaluation
- Study visit and blood collection within 3 weeks (21 days) of ACR BI-RADS assessment
- Patient agrees to return for diagnostic follow-up and blood collection at 6 months unless a positive cancer diagnosis is made between study visits 1 and 2. Individuals diagnosed with LCIS and DCIS will agree to return for visit 2
- Samples collected under IRB approval and Informed Consent
- Testing performed under IRB approval or waiver (as applicable)
Exclusion Criteria:
- Adults from 50 years of age or older and below 25 years of age
- Final breast evaluation results other than a ACR BI-RADS Category 3 or 4
- Subjects that have had a breast biopsy performed at any time prior to the study visit
- Samples not collected under IRB approval and Informed Consent
- Testing not performed under IRB approval or waiver (as applicable)
- Prior breast cancer diagnosis.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Breast Cancer
ACR BI-RAD Category 3 or 4 result
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Training
Periodo de tiempo: Baseline
|
Part I: Establish an acceptable algorithm for generation of a single numerical score from the combination of the 5 cancer biomarkers that comprise the dtectDX-Breast Assay Part II: Define a numerical score cutoff that differentiates malignant from nonmalignant breast cancer in this population of woman.
|
Baseline
|
Blinded Validation
Periodo de tiempo: 6 months
|
Demonstrate proof-of-concept for use of the dtectDx-Breast Assay to assess likelihood of breast cancer malignancy in conjunction with the physicians clinical and radiological evaluations.
|
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Clinical Sensitivity/Specificity
Periodo de tiempo: Baseline
|
Demonstrate the numerical score, collaborated via proprietary algorithm (greater then 60 is an elevated score, less then 60 is a normal score), for the dtectDx-Breast Assay increases the likelihood of malignant breast cancer detection when used adjunctively with the assessment of BI-RADS Categories 3 and 4 compared to the assessment of BI-RADS Categories 3 and 4 alone.
|
Baseline
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- dtectDx-Breast-001
- ProvistaDx (Otro identificador: ProvistaDx)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos